MBIO Insider Trading
Insider Ownership Percentage: 0.21%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Mustang Bio Share Price & Price History
Current Price: $1.16
Price Change: ▼ Price Decrease of -0.005 (-0.43%)
As of 04/29/2025 11:30 AM ET
Mustang Bio Insider Trading History
Mustang Bio Institutional Trading History
Data available starting January 2016
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Read More on Mustang Bio
Volume
48,745 shs
Average Volume
325,946 shs
Market Capitalization
$3.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.14